Business Description
Verona Pharma PLC
Share Class Description:
STU:I9SA: ADRDescription
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.97 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.23 | |||||
| Debt-to-EBITDA | -0.88 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 30.9 | |||||
| 3-Year EPS without NRI Growth Rate | 28.5 | |||||
| 3-Year FCF Growth Rate | 22.7 | |||||
| 3-Year Book Growth Rate | -1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 92.43 | |||||
| 9-Day RSI | 80.43 | |||||
| 14-Day RSI | 69.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 18.4 | |||||
| Quick Ratio | 18.4 | |||||
| Cash Ratio | 17.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.6 | |||||
| Shareholder Yield % | -2.05 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -24.63 | |||||
| ROA % | -20.9 | |||||
| ROIC % | -312.93 | |||||
| ROC (Joel Greenblatt) % | -3654.63 | |||||
| ROCE % | -20.38 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 5.45 | |||||
| Price-to-Tangible-Book | 5.46 | |||||
| EV-to-EBIT | -17.35 | |||||
| EV-to-EBITDA | -17.58 | |||||
| EV-to-Forward-Revenue | 86.02 | |||||
| EV-to-FCF | -17.63 | |||||
| Price-to-Net-Current-Asset-Value | 5.92 | |||||
| Price-to-Net-Cash | 6.45 | |||||
| Earnings Yield (Greenblatt) % | -5.76 | |||||
| FCF Yield % | -4.73 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Verona Pharma PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.738 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 69.87 | ||
| 14-Day ATR (€) | 0.423633 | ||
| 20-Day SMA (€) | 11.64 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 10.4 - 15.1 | ||
| Shares Outstanding (Mil) | 81.08 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Verona Pharma PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Verona Pharma PLC Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Verona Pharma PLC Frequently Asked Questions
What is Verona Pharma PLC(STU:I9SA)'s stock price today?
The current price of STU:I9SA is €14.30. The 52 week high of STU:I9SA is €15.10 and 52 week low is €10.40.
When is next earnings date of Verona Pharma PLC(STU:I9SA)?
The next earnings date of Verona Pharma PLC(STU:I9SA) is 2024-08-02 Est..
Does Verona Pharma PLC(STU:I9SA) pay dividends? If so, how much?
Verona Pharma PLC(STU:I9SA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers